Enhancing Cancer Therapy: Antibody Drug Conjugates and Immunotherapies for Resistant Cancers

Antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic agents, offer a targeted approach to cancer therapy, aiming to deliver drugs directly to tumor cells while minimizing off-target effects. Despite the considerable potential of ADCs, challenges like resistance development and their limited efficacy against solid tumors persist. Recent approaches have explored combining ADCs with immuno-therapies, such as immune checkpoint inhibitors and cellular immune engagers, to enhance the immunogenicity of the tumor microenvironment and promote a stronger immune response against cancer cells.This Research Topic aims to delve into the innovative integration of ADCs and various forms of immunotherapy to address the existing limitations in cancer treatment. The focus is on the synergistic interactions between these therapies that not only enhance tumor cell eradication but also boost the immune system's response, potentially leading to more durable outcomes and overcoming resistance to conventional treatments. By studying the mechanisms of action, researchers can optimize these combinations to improve efficacy and achieve more durable responses in cancers resistant to single-agent treatments. This effort involves understanding optimal dosing, sequencing strategies, and identifying predictive biomarkers to maximize therapeutic benefit while minimizing toxicity.To foster advancements in this promising field, this Research Topic will cover a wide array of pertinent themes, including:o Mechanisms underlying the synergy between ADCs and immunotherapieso Preclinical and clinical assessments of ADC-immunotherapy combination therapieso Strategies for optimal dosing and treatment sequencingo Exploration of resistance mechanisms to combination therapieso Identification of predictive biomarkers for better patient stratificationWe welcome submissions of original research, review articles, and case studies that contribute to these areas. This initiative is intended to propel forward the integration of ADCs with immunotherapy, offering novel therapeutic strategies for patients battling complex cancer types.Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic. Topic editors: Tamar Uziel, Christine Lee Hann, Jack Shih-Hsun Chen, Pearlie Epling-Burnette Source: https://www.frontiersin.org/research-topics/68326/enhancing-cancer-therapy-antibody-drug-conjugates-and-immunotherapies-for-resistant-cancers